Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ultragenyx Gets Second Drug Approval; Crysvita With Kyowa Hakko Kirin

Executive Summary

Ultragenyx already has a sales team in place to market its second commercial drug Crysvita (burosumab) – partnered with Kyowa Hakko Kirin – following its April 17 FDA approval for the treatment of pediatric and adult patients with x-linked hypophosphatemia (XLH).

Advertisement

Related Content

2018 Saw Record Launches, But No Big Splash
Rare Disease Roundtable: How Rare Is Too Rare?
Finance Watch: VC Mega-Deals Launch Biopharma Firms With New Takes On CV, Genetic Diseases
Keeping Track: A Fresh Wave Of Approvals
Novartis Stockpiling Priority Review Vouchers
Kyowa Hakko Kirin, Ultragenyx To Develop Treatment For X-linked Hypophosphatemia

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC122916

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel